Building Hope.

Trovagene is developing precision cancer therapeutics to improve cancer care.

Our Mission

Our mission is to transform cancer therapeutics to improve cancer care.

Our Therapeutics

We are a clinical stage precision medicine biotechnology company developing oncology therapeutics for hematologic and solid tumor cancers. Beginning with our lead drug candidate PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor, we are on a journey to develop new treatment options to help transform cancer care.

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. Now with the FDA’s granting of orphan drug designation for PCM-075 to treat patients with Acute Myeloid Leukemia (AML), and initiation of our Phase 1b/2 clinical trial, we are moving forward with our clinical development program.

We optimize drug development by leveraging our significant experience and expertise in biomarker and Precision Cancer Medicine® (PCM) technology to address the need for new therapeutic options to treat hematologic and solid tumor cancers.

What is PCM-075, a PLK1 Inhibitor?

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. It is an oral, highly selective competitive inhibitor of the PLK1 enzyme which is commonly overexpressed in several different hematologic and solid tumor cancers.

These attributes combined with potential synergy in combination with numerous chemotherapeutics and targeted therapies makes PCM-075 a highly attractive drug candidate.

Orphan Drug Designation in AML

On September 28th, 2017, the FDA granted Orphan Drug Designation to our PLK1 inhibitor, PCM-075 for the treatment of Acute Myeloid Leukemia, an important milestone in our clinical development plan.

PCM-075 Clinical Evidence

PCM-075 has the potential to be a safe and effective treatment for hematologic and solid tumor cancers due to high selectivity for PLK1, relatively short half-life, and more.

Combination Therapy Opportunities

PCM-075 may be synergistic and enhance the efficacy of current and future standard-of-care therapies.

In Our Pipeline

We are developing PCM-075 for both hematologic and solid tumor cancers. Our Precision Cancer Medicine® technology allows us to measure genetic fragments of cancer tumors to identify patients most likely to respond to therapy.

News

Jun 15, 2018

Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced…

Learn More

May 17, 2018

Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the…

Learn More

Apr 17, 2018

Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the…

Learn More